{"title":"Metamorphopsia after surgery for rhegmatogenous retinal detachment.","authors":"Han-Tao Zhou, Zhong Lin","doi":"10.18240/ijo.2025.01.21","DOIUrl":null,"url":null,"abstract":"<p><p>Improvements in surgical techniques have led to 90% success in the surgical repair of rhegmatogenous retinal detachment (RRD). However, anatomical reattachment of the retina does not ensure complete recovery of visual function. The incidence of metamorphopsia remains the most common postoperative complaint, from 24% to 88.6%. Currently, the risk factors of metamorphopsia are categorized into macular involvement, retinal shift, outer retinal folds, subretinal fluid, secondary epiretinal membrane, outer retinal layer damage, and surgical approach. The associations of metamorphopsia with postoperative best-corrected visual acuity and postoperative vision-related quality of life were still controversial. The most popular methods for assessment of metamorphopsia remain the Amsler grid and M-Charts. Most treatments cannot progress beyond the management of negative visual sensations, through methods such as occlusion therapy and aniseikonia-correcting spectacles. The main treatment approach involves RRD prevention and the management of risk factors that can lead to postoperative metamorphopsia after RRD repair. Additional research concerning metamorphopsia treatment, further upgrades of auxiliary inspection methods, and more accurate microstructural assessments are needed to address this common complication.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 1","pages":"168-177"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672081/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.01.21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Improvements in surgical techniques have led to 90% success in the surgical repair of rhegmatogenous retinal detachment (RRD). However, anatomical reattachment of the retina does not ensure complete recovery of visual function. The incidence of metamorphopsia remains the most common postoperative complaint, from 24% to 88.6%. Currently, the risk factors of metamorphopsia are categorized into macular involvement, retinal shift, outer retinal folds, subretinal fluid, secondary epiretinal membrane, outer retinal layer damage, and surgical approach. The associations of metamorphopsia with postoperative best-corrected visual acuity and postoperative vision-related quality of life were still controversial. The most popular methods for assessment of metamorphopsia remain the Amsler grid and M-Charts. Most treatments cannot progress beyond the management of negative visual sensations, through methods such as occlusion therapy and aniseikonia-correcting spectacles. The main treatment approach involves RRD prevention and the management of risk factors that can lead to postoperative metamorphopsia after RRD repair. Additional research concerning metamorphopsia treatment, further upgrades of auxiliary inspection methods, and more accurate microstructural assessments are needed to address this common complication.
期刊介绍:
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.